Chronic myelogenous leukemia (CML) is a chronic myeloproliferative disorder that is characterized by leukocytosis, thrombocytosis and anemia with myeloid hyperplasia in the bone marrow. 1 It affects 4500 people in the United States each year. Leukocytosis is invariably present with varying numbers of immature myeloid cells in the blood. Usually o5% circulating blasts are noted. Generally, there is a sustained and progressive rise in the white count; however, in a few instances there may be a periodic oscillation in peripheral blood leukocytes with or without antileukemic therapy. 2 The platelet count is typically high or normal, but on occasion severe thrombocytopenia may be seen. 3 Most patients are anemic and on occasion require red blood cell transfusion. The gold standard for diagnosis of CML is detection of the Philadelphia chromosome (t(9;22) (q34.1;q11.21)) and/or the Bcr-Abl1 hybrid gene.
We report a case of a 43-year-old male with a clinical picture resembling a myelodysplastic syndrome who presented with severe thrombocytopenia, mild anemia, normal WBC, splenomegaly and only erythroid hyperplasia in the bone marrow. Surprisingly, he was found to have t(9;22) on cytogenetic analysis. This patient was treated with imatinib mesylate and responded well. All blood counts returned to normal with disappearance of the cytogenetic abnormality. This response has persisted for more than 6 years. To the best of our knowledge, this presentation and response has not been described previously.
A 43-year-old man with no significant past medical history, presented on July 13, 2001 with a 10-day history of fatigue and easy bruising. He also described a recent weight loss of 10-15 lb. He denied fever, chills, night sweats or recurrent infections. He denied occupational exposure to toxic fumes or solvents. His family history was significant for lung cancer in his father and breast cancer in his mother. On physical examination, he appeared healthy but anxious. He was mildly icteric. There was no peripheral lymphadenopathy. Abdominal examination revealed 4 cm splenomegaly with no tenderness. Skin examination revealed mild ecchymoses. Rectal exam was unremarkable and stools were negative by Hemoccult testing.
On presentation his white blood cell count was 5.6 Â 10 9 l
À1
with 38% segs, 19% bands, 3% lymphocytes, 5% monocytes, 3% metamyelocytes, 3% myelocytes, 1% blasts and 36% nucleated red cells. Hemoglobin was 10.3 g dl À1 with a striking mean corpuscular volume of 118 and platelets were 16 Â 10 9 l
. Lactate dehydrogenase was normal at 179. Coombs testing was negative. A liver panel was normal except for a bilirubin of 1.6, which was mostly indirect. Renal function was normal. Human immunodeficiency virus 1 and 2 were negative. An serum protein electrophoresis (SPEP) was normal. Urine protein electrophoresis was negative. Antinuclear antibodies (ANA) as well as testing for cytomegalovirus, toxoplasmosis and viral hepatitis were negative.
On review of his peripheral smear, there was marked macrocytosis with anisocytosis and polychromatophilia. There was an occasional spherocyte and 36% nucleated red cells, some of which were dysplastic. He had rare basophils, myeloblasts and myelocytes. Platelets were markedly reduced but without abnormal forms. A bone marrow aspirate was hypercellular (95%) with reduced megakaryocytes. There was marked erythroid hyperplasia with mild dysplasia but without significant immaturity in the erythroid precursors. The myeloid/ erythroid (M/E) ratio was 0.2:1. Erythroid precursors constituted 85% of cells. There was impaired maturation in the myeloid series but only 1.5% myeloblasts. An iron stain showed 7% of erythroid precursors to be ringed sideroblasts. Bone marrow aspirate and biopsy at the time of diagnosis.
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On the basis of peripheral blood and marrow findings, the patient was believed to have a myelodysplastic syndrome. Subsequently, the platelet count fell to 12k and he received one dose of intravenous Solumedrol and platelet transfusions. He was urgently referred to the Western Pennsylvania Cancer Institute (WPCI) for consideration of stem cell transplantation. In the interim, the patient received platelet transfusions on three occasions but did not require any RBC transfusions. When seen in Pittsburgh on July 23 (10 days after the initial presentation), the WBC was 6.9 Â 10 9 l, hemoglobin was 11.2 with a mean corpuscular volume of 118 and platelet count was 34k (1 day posttransfusion). A review of these data and marrow aspirate and biopsy was consistent with a myelodysplastic syndrome. Surprisingly, a fluorescent in situ hybridization analysis for Bcr-Ab1 fusion gene was positive in 94% of cells. Subsequent cytogenetic analysis of the peripheral blood on July 23 was positive for t(9;22) in 50% of the cells and reverse transcription-PCR was positive for the P210 Bcr-Abl protein. Thus, the patient appeared to have a myelodysplastic picture clinically, yet had a cytogenetic finding indicative of CML. It was decided to initiate a trial of imatinib mesylate, although there was no known precedent for this approach in a patient whose disease manifestation was severe thrombocytopenia, without leukocytosis.
The patient was started on imatinib mesylate 400 mg once daily on August 3 (20 days after the initial presentation). Imatinib was increased to 600 mg a day within a period of 4 weeks. Six weeks after starting imatinib mesylate, the WBC was 1.7 Â 10 9 l À1 , hemoglobin was 9.9 g dl À1 and platelet count was 8 Â 10 9 l
À1
. He continued to require platelet transfusions for 2 months. At that point, it was uncertain if the decline in counts was secondary to imatinib or disease progression. After 2 months of treatment, a few nucleated red cells and myeloid precursors were present in the peripheral blood; however, Platelets over the last 6 years.
Letters to the Editor fluorescent in situ hybridization testing remained 80% positive for the t(9;22) translocation. After 5 months, there was a near complete hematological response with a WBC of 3.2 Â 10 9 l À1 , hemoglobin of 13 g dl À1 and platelet count of 158 Â 10 9 l À1 . Fluorescent in situ hybridization testing revealed complete cytogenetic remission.
After 6 months of therapy, a peripheral smear showed normocytic, normochromic RBCs without significant poikilocytosis or polychromasia. There were no nucleated RBCs and WBC morphology and maturation were normal. Platelet number and morphology were also normal. At that time, a repeat bone marrow biopsy showed improved cellularity of 70%. There was mild megakaryocytic hyperplasia with normal morphology. All three cell lines were well represented. The M/E ratio was 1.9:1. Erythroid precursors constituted approximately 29% of cells. Iron stores were slightly increased with few siderocytes and occasional ringed sideroblasts (less than 5% of all nucleated RBCs). Fluorescent in situ hybridization analysis remained negative.
After achieving complete remission, the dose of imatinib was reduced to 400 mg daily. Six years after starting treatment with imatinib, the patient remains in molecular remission by reverse transcription-PCR testing of the peripheral blood. The counts at this time are a WBC of 7.00 Â 10 9 l
, hemoglobin of 14.2 g dl
and platelet count of 226k. The chronic phase of CML is characterized by a marked increment in the pool of committed myeloid progenitors, leading to peripheral blood leukocytosis and often thrombocytosis with a prominent left shift in the differential count. Typical findings include anemia, WBC above 100 Â 10 9 l À1 and platelet count above 600 Â 10 9 . 4, 5 Our patient, however, presented with a striking macrocytic anemia, a normal leukocyte count with mild left shift and marked thrombocytopenia with easy bruising. There were also numerous nucleated RBCs, which is uncommon for CML. Moreover, there was no basophilia, eosinophilia or monocytosis.
The typical bone marrow appearance in CML reveals hypercellularity (75-100%) with marked myeloid and megakaryocytic hyperplasia. An increased M/E ratio of 10-30:1 is noted in almost all patients. Our case, in contrast, showed hypercellularity with marked erythroid hyperplasia and a M/E ratio of 0.2:1. Usually, there is marked shift toward myeloid immaturity with the marrow blast percentage being generally normal or slightly elevated, whereas in our case, we found 1.5% blasts and 85% erythroid precursors.
A unique feature of CML has been the occasional marked cyclic oscillation in the leukocyte count without antileukemic therapy, especially during the early or evolutionary stages of CML. 2 It is possible that our patient had oscillation in his WBC at the time of presentation that may have led to confusion in the diagnosis. However, this seems unlikely as the Hemoglobin over the last 6 years.
Figure 5
Bone marrow aspirate and biopsy 6 months after starting treatment with imatinib.
Letters to the Editor marrow does not develop myeloid hypoplasia, during a nadir in the WBC as noted in the previously reported cases with cyclic oscillation. 2 As noted, the severe thrombocytopenia and macrocytic anemia are unusual in the chronic phase of CML. Moreover, the marrow findings of intense erythroid hyperplasia and a reduction of myeloid cells in the marrow are atypical for a diagnosis of CML. However, given the presence of the Philadelphia chromosome and typical picture Bcr-abl translocation with a striking response to imatinib mesylate, this case represents what we have termed an 'erythroid variant' of CML. To our knowledge, this appears to be the first case that has been observed and has responded to imatinib mesylate. The patient remains in complete hematologic and molecular remission for more than 6 years on continued treatment with imatinib (Figures 1-5) .
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